# Genfit clinical trials: 23 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Genfit as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genfit: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/genfit

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 9, 2026 | NCT07694297 | Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of... | Genfit | Phase 2 | Not yet recruiting | Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694297) |
| August 7, 2025 | NCT07110441 | Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers | Genfit | Phase 1 | Completed | Acute-on-Chronic Liver Failure | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07110441) |
| May 23, 2025 | NCT06987968 | A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic... | Genfit | Phase 2 | Terminated | Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987968) |
| June 12, 2023 | NCT05900050 | Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® | Genfit | Phase 2 | Terminated | Acute-On-Chronic Liver Failure, Ascites | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05900050) |
| May 24, 2023 | NCT05874414 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Genfit | Phase 1/2 | Recruiting | Cholangiocarcinoma | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05874414) |
| May 10, 2022 | NCT05368935 | Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects | Genfit | Phase 1 | Completed | Renal Impairment, Renal Disease, Kidney Disease | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05368935) |
| November 11, 2021 | NCT05116826 | Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients | Genfit | Phase 1 | Completed | Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05116826) |
| November 21, 2019 | NCT04171752 | Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers | Genfit | Phase 1 | Completed | Geriatrics, Healthy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04171752) |
| June 14, 2019 | NCT03985969 | Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin | Genfit | Phase 1 | Completed | Drug-drug Interaction | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03985969) |
| May 16, 2019 | NCT03953456 | Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL) | Genfit | Phase 2 | Terminated | Non-Alcoholic Fatty Liver | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03953456) |
| March 21, 2019 | NCT03883607 | Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) | Genfit | Phase 2 | Terminated | Non Alcoholic Steatohepatitis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03883607) |
| February 18, 2019 | NCT03844555 | Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients | Genfit | Phase 1 | Completed | Renal Impairment, Renal Insufficiency, Kidney Diseases, Pharmacokinetics | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03844555) |
| December 5, 2018 | NCT03765671 | Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients | Genfit | Phase 1 | Completed | Hepatic Impairment, Liver Disease, Pharmacokinetics | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03765671) |
| April 21, 2017 | NCT03124108 | Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to... | Genfit | Phase 2 | Completed | Primary Biliary Cholangitis (PBC) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03124108) |
| March 10, 2016 | NCT02704403 | Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) | Genfit | Phase 3 | Terminated | Nonalcoholic Steatohepatitis (NASH) With Fibrosis | 2,157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02704403) |
| May 20, 2014 | NCT02142127 | Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers | Genfit | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02142127) |
| March 19, 2014 | NCT02091310 | Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers | Genfit | Phase 1 | Completed | Healthy Volunteers | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02091310) |
| September 27, 2012 | NCT01694849 | Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) | Genfit | Phase 2 | Completed | Non-Alcoholic Steatohepatitis (NASH) | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01694849) |
| November 18, 2011 | NCT01474161 | Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505 | Genfit | Phase 1 | Completed | Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases, Obese, Dyslipidemia | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01474161) |
| January 12, 2011 | NCT01275469 | Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. | Genfit | Phase 2 | Completed | Impaired Glucose Tolerance, Abdominal Obesity | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01275469) |
| January 7, 2011 | NCT01271777 | Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity | Genfit | Phase 2 | Completed | Insulin Resistance, Abdominal Obesity | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01271777) |
| January 7, 2011 | NCT01271751 | Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity | Genfit | Phase 2 | Completed | Atherogenic Dyslipidaemia, Abdominal Obesity | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01271751) |
| December 16, 2010 | NCT01261494 | Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus | Genfit | Phase 2 | Completed | Type II Diabetes Mellitus | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01261494) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 11 |
| Phase 3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 5 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Non-alcoholic Fatty Liver Disease | 4 |
| Liver Diseases | 4 |
| Fibrosis | 4 |
| Acute-On-Chronic Liver Failure | 4 |
| Obesity, Abdominal | 3 |
| Kidney Diseases | 3 |
| Renal Insufficiency | 3 |
| Diabetes Mellitus, Type 2 | 2 |
| Metabolic Diseases | 2 |
| Cardiovascular Diseases | 2 |
| Glucose Intolerance | 2 |
| Glucose Metabolism Disorders | 1 |
| Liver Cirrhosis, Biliary | 1 |
| Cholangiocarcinoma | 1 |
| Bile Duct Neoplasms | 1 |
| Ascites | 1 |
| Liver Failure | 1 |
| Insulin Resistance | 1 |
| Hepatic Encephalopathy | 1 |
| Wounds and Injuries | 1 |
| Obesity | 1 |
| Dyslipidemias | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Corporate gift suppliers in the United States](https://specstream.ai/data/businesses/corporate-gift-suppliers/united-states)
- [Immigration law firms in the United States](https://specstream.ai/data/businesses/immigration-law-firms/united-states)
- [Preschools in the United States](https://specstream.ai/data/businesses/preschools/united-states)
